Enteric-coated mycophenolate sodium (EC-MPS)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Transplantation
Conditions
Pancreas Transplantation, Kidney Transplantation
Trial Timeline
Nov 1, 2005 → Jan 1, 2008
NCT ID
NCT00267150About Enteric-coated mycophenolate sodium (EC-MPS)
Enteric-coated mycophenolate sodium (EC-MPS) is a phase 3 stage product being developed by Novartis for Pancreas Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00267150. Target conditions include Pancreas Transplantation, Kidney Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00405652 | Phase 3 | Completed |
| NCT00529269 | Approved | Completed |
| NCT00369278 | Phase 3 | Completed |
| NCT00537862 | Approved | Completed |
| NCT00267150 | Phase 3 | Completed |
| NCT00149968 | Approved | Completed |
| NCT00238953 | Approved | Completed |
| NCT00239083 | Approved | Completed |
| NCT00149942 | Approved | Completed |
| NCT00150020 | Approved | Completed |
| NCT00154206 | Approved | Completed |
| NCT00154232 | Approved | Completed |
| NCT00150007 | Approved | Completed |
| NCT00284921 | Phase 3 | Terminated |
| NCT00240955 | Approved | Completed |
| NCT00312143 | Approved | Completed |
| NCT00154245 | Approved | Completed |
| NCT00239070 | Phase 3 | Completed |
| NCT00239018 | Approved | Completed |
| NCT00238940 | Phase 3 | Completed |
Competing Products
20 competing products in Pancreas Transplantation